阿尔茨海默病:完全回忆的尝试
Alexey P Bolshakov1, Konstantin Gerasimov1,2, Yulia V Dobryakova1
1Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.
Journal of Alzheimer's disease : JAD
|September 13, 2024
概括
这篇评论探讨了阿尔茨海默病 (AD) 的机制,从感官损失到像粉样蛋白斑块和团这样的分子变化. 它检查了神经退行和潜在的治疗点,包括铁化.
科学领域:
- 神经科学是一个神经科学.
- 病理学 病理学 病理学
- 分子生物学分子生物学
背景情况:
- 阿尔茨海默病 (AD) 的特点是逐渐的神经退行.
- 早期的感官障碍和以后的分子事件,包括粉样斑块和团,是AD的标志.
- 神经元损失会影响大脑的关键区域,影响认知功能.
研究的目的:
- 审查和综合有关阿尔茨海默病发病和进展的当前假设.
- 探索分子机制,包括蛋白质聚合和氧化应激.
- 研究特定神经元群体的作用和潜在的治疗干预措施.
主要方法:
- 文献综述和现有假设的综合.
- 分析与AD病变发生相关的分子事件.
- 检查特定神经元通路中的神经退行性变化.
主要成果:
- 感官障碍可能在AD.特征分子病理学之前.
- 粉样质斑块,团,希拉诺体和氧化应激是关键的病理特征.
- 退化会影响胆固醇,胰岛素,血清和神经质神经元.
- 铁的积累和交感系统的参与被讨论为潜在的疾病触发因素.
- 神经元中的补偿机制可能在AD进展中发挥作用.
结论:
- 了解AD的多方面的机制对于开发有效的治疗方法至关重要.
- 准分子事件,神经炎症和特定的神经元通路可能会带来治疗效益.
- 对铁化和交感神经系统调制的进一步研究有望缓解AD进展.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.氨基化物 氨基化物星球细胞是星球细胞.胆固醇神经元是一种神经元.神经退行症的神经退行症诺拉德能神经元 (noradrenergic neurons) 是一种神经元.氧化应激是一种氧化应激.这是同情系统的同情系统.病症是一种病症.更多相关视频
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
14.8K
06:46Automated, Long-term Behavioral Assay for Cognitive Functions in Multiple Genetic Models of Alzheimer's Disease, Using IntelliCage
Published on: August 4, 2018
12.1K
相关概念视频
Alzheimer's Disease: Overview
452
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
452
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170
Dementia
107
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
107
